503 related articles for article (PubMed ID: 21677277)
1. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
2. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice.
Murphy KT; Cobani V; Ryall JG; Ibebunjo C; Lynch GS
J Appl Physiol (1985); 2011 Apr; 110(4):1065-72. PubMed ID: 21270350
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function.
Murphy KT; Koopman R; Naim T; Léger B; Trieu J; Ibebunjo C; Lynch GS
FASEB J; 2010 Nov; 24(11):4433-42. PubMed ID: 20624929
[TBL] [Abstract][Full Text] [Related]
4. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
6. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model.
Chen T; Li B; Xu Y; Meng S; Wang Y; Jiang Y
Oncol Rep; 2018 Aug; 40(2):1129-1137. PubMed ID: 29845270
[TBL] [Abstract][Full Text] [Related]
7. Chronic Alcohol Consumption Enhances Skeletal Muscle Wasting in Mice Bearing Cachectic Cancers: The Role of TNFα/Myostatin Axis.
Li Y; Zhang F; Modrak S; Little A; Zhang H
Alcohol Clin Exp Res; 2020 Jan; 44(1):66-77. PubMed ID: 31657476
[TBL] [Abstract][Full Text] [Related]
8. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
[TBL] [Abstract][Full Text] [Related]
10. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Chacon-Cabrera A; Fermoselle C; Urtreger AJ; Mateu-Jimenez M; Diament MJ; de Kier Joffé ED; Sandri M; Barreiro E
J Cell Physiol; 2014 Nov; 229(11):1660-72. PubMed ID: 24615622
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure.
Heineke J; Auger-Messier M; Xu J; Sargent M; York A; Welle S; Molkentin JD
Circulation; 2010 Jan; 121(3):419-25. PubMed ID: 20065166
[TBL] [Abstract][Full Text] [Related]
14. Reduced sucrose nonfermenting AMPK-related kinase (SNARK) activity aggravates cancer-induced skeletal muscle wasting.
Alves CRR; MacDonald TL; Nigro P; Pathak P; Hirshman MF; Goodyear LJ; Lessard SJ
Biomed Pharmacother; 2019 Sep; 117():109197. PubMed ID: 31387190
[TBL] [Abstract][Full Text] [Related]
15. Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-κB and activating SIRT1.
Chen C; Ju R; Zhu L; Li J; Chen W; Zhang DC; Ye CY; Guo L
Naunyn Schmiedebergs Arch Pharmacol; 2017 Apr; 390(4):423-433. PubMed ID: 28124088
[TBL] [Abstract][Full Text] [Related]
16. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.
Smith RC; Lin BK
Curr Opin Support Palliat Care; 2013 Dec; 7(4):352-60. PubMed ID: 24157714
[TBL] [Abstract][Full Text] [Related]
17. Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice.
Murphy KT; Ryall JG; Snell SM; Nair L; Koopman R; Krasney PA; Ibebunjo C; Holden KS; Loria PM; Salatto CT; Lynch GS
Am J Pathol; 2010 May; 176(5):2425-34. PubMed ID: 20363926
[TBL] [Abstract][Full Text] [Related]
18. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
19. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
